Shanghai Serum Bio-Technology Co., Ltd. (SHA:688163)
44.56
-0.31 (-0.69%)
At close: Jun 23, 2026
SHA:688163 Revenue
Shanghai Serum Bio-Technology had revenue of 27.09M CNY in the quarter ending March 31, 2026, with 5.75% growth. This brings the company's revenue in the last twelve months to 197.68M, up 1.77% year-over-year. In the year 2025, Shanghai Serum Bio-Technology had annual revenue of 196.21M with 0.66% growth.
Revenue (ttm)
197.68M
Revenue Growth
+1.77%
P/S Ratio
24.39
Revenue / Employee
599.02K
Employees
330
Market Cap
4.82B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 196.21M | 1.29M | 0.66% |
| Dec 31, 2024 | 194.92M | 4.77M | 2.51% |
| Dec 31, 2023 | 190.14M | 15.92M | 9.14% |
| Dec 31, 2022 | 174.22M | -34.47M | -16.52% |
| Dec 31, 2021 | 208.69M | 23.13M | 12.47% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Anhui Huaheng Biotechnology | 2.95B |
| Novogene | 2.26B |
| Wuhan Hvsen Biotechnology | 1.74B |
| Shenzhen Weiguang Biological Products | 1.26B |
| Wuhan Keqian Biology Co.,Ltd | 932.09M |
| Beijing Konruns Pharmaceutical | 917.99M |
| Jiangsu Aidea Pharmaceutical Group | 699.33M |
| PharmaResources (Shanghai) | 691.21M |